Arbutus Biopharma Corporation (ABUS) Profit Margins
Over the twelve months to 2026-06-30, Arbutus Biopharma Corporation (ABUS) had operating margin 82.0%, net margin 84.2%, free cash flow margin -13.6%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABUSArbutus Biopharma CorporationFollow ABUS — free
—
Price chart with a free account
- Market cap
- 831.0M
- P/E TTM
- 5.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 96.0% | 93.4% | — | — | — | — | — | 92.2% | 83.0% | 94.3% | 99.6% | — | 21.1% | — | |
| Operating margin | -78.6% | -223.6% | -446.5% | -32973.8% | -1036.7% | -1510.2% | -2394.0% | -836.1% | -669.1% | -167.8% | -430.5% | -1236.7% | -271.0% | 82.0% | |
| Net margin | -90.9% | -259.7% | -269.5% | -25765.5% | -788.9% | -959.8% | -2557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% | 84.2% | |
| FCF margin | -48.3% | -90.1% | -252.1% | -4150.3% | -522.5% | -1160.7% | -1191.1% | -747.3% | -622.0% | -91.9% | -479.3% | -1053.8% | -281.5% | -13.6% |
USD millions · SEC XBRL
Arbutus Biopharma Corporation — questions
- What is Arbutus Biopharma Corporation's operating margin?
- 82.0% over the twelve months to 2026-06-30.
- What is Arbutus Biopharma Corporation's net profit margin?
- 84.2% over the twelve months to 2026-06-30.
Every figure on this page comes from Arbutus Biopharma Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.